Zhejiang Jiaxing Yunying Biomedical Technology Co., Ltd.

Based in Jiaxing, China and founded in 2023, Zhejiang Jiaxing Yunying Biomedical Technology Co. , Ltd. was established to provide healthcare services and pharmaceutical distribution in the Yangtze River Delta region. The company focuses on oncology precision medicine and integrates biotechnology applications such as gene mutation testing, gene methylation analysis, and gene editing technologies to support cancer diagnosis and treatment.

Since its establishment, the company has participated in external quality assessment programs organized by national and international clinical and pathology institutions and has provided diagnostic services for hundreds of thousands of oncology patients. In March 2026, Zhejiang Jiaxing Yunying Biomedical Technology Co. , Ltd. closed nearly CNY 100 million in Strategic Investment.

The company conducts pharmaceutical wholesale and retail operations while also providing biotechnology-based diagnostic and healthcare services. Its offerings include precision cancer screening, genetic mutation and methylation testing, targeted therapy testing, and related diagnostic services. The firm also engages in the research, development, and sales of Class I medical devices and participates in biotechnology applications related to oncology precision medicine. The company generates revenue from pharmaceutical wholesale and retail activities, genetic and diagnostic testing services, sales of medical devices, and healthcare service solutions related to oncology precision medicine.